Immuno-epidemiological life-history and the dynamics of SARS-CoV-2 over the next five years

Chadi M. Saad-Roy,¹* Caroline E. Wagner,^{2,3*} Rachel E. Baker,^{2,3} Sinead E. Morris,⁴ Jeremy Farrar⁵ Andrea L. Graham,² Simon A. Levin,² C. Jessica E. Metcalf,^{2,6} Bryan T. Grenfell^{2,6,7†}

 ¹Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton NJ 08540, USA
 ²Department of Ecology and Evolutionary Biology, Princeton University, Princeton NJ 08544, USA
 ³Princeton Environmental Institute, Princeton University, Princeton NJ 08544, USA
 ⁴Department of Pathology and Cell Biology, Columbia University Medical Center, New York NY 10032, USA
 ⁵ The Wellcome Trust, London, UK
 ⁶Princeton School of Public and International Affairs, Princeton University, Princeton NJ 08544, USA

*These authors contributed equally to this work [†]To whom correspondence should be addressed; E-mail: grenfell@princeton.edu

Uncertainty in the immune response to SARS-CoV-2 may have implications
 for future outbreaks. We use simple epidemiological models to explore estimates for the magnitude and timing of future Covid-19 cases given different
 impacts of the adaptive immune response to SARS-CoV-2 as well as its in-

teraction with vaccines and nonpharmaceutical interventions. We find that
 variations in the immune response to primary SARS-CoV-2 infections and a
 potential vaccine can lead to dramatically different immunity landscapes and
 burdens of critically severe cases, ranging from sustained epidemics to near
 elimination. Our findings illustrate likely complexities in future Covid-19 dy namics, and highlight the importance of immunological characterization be yond the measurement of active infections for adequately characterizing the
 immune landscape generated by SARS-CoV-2 infections.

13 Introduction

The current Covid-19 pandemic caused by the novel SARS-CoV-2 betacoronavirus (β -CoV) has resulted in substantial morbidity and mortality, with over ten million confirmed cases worldwide at the time of writing. In order to curb viral transmission, non-pharmaceutical interventions (NPIs) including business and school closures, restrictions on movement, and total lockdowns have been implemented to various degrees around the world. Major efforts to develop effective vaccines and antivirals are ongoing.

20

Understanding the future trajectory of this disease requires knowledge of the population-21 level landscape of immunity generated by the life histories of SARS-CoV-2 infection or vac-22 cination among individual hosts, particularly in the context of the acquisition, re-transmission, 23 and clinical severity of secondary infections. The nature of acquired immune responses fol-24 lowing natural infection varies substantially among pathogens. At one end of this immune 25 spectrum, natural infection with measles (1) or smallpox (2) virus results in lifelong protec-26 tion from the re-acquisition and re-transmission of secondary infections. Many other infections 27 (e.g. influenza (3), RSV (4)) confer imperfect or transient clinical and transmission-blocking 28

²⁹ immunity. Finally, phenomena such as antibody-dependent enhancement (ADE) associated ³⁰ with prior natural infection (e.g. dengue (5)) or a vaccine (e.g. RSV (6)) could result in more ³¹ clinically severe secondary infections. Furthermore, the immunity conferred by vaccines to var-³² ious pathogens rarely provides complete protection against reinfection and/or disease (9), and ³³ this protection may be inferior to that acquired following natural infection (*10*). Nevertheless, ³⁴ imperfect vaccines that reduce both the clinical severity and transmissibility of subsequent in-³⁵ fections (if they do occur) can still provide population-level disease protection (9, 11).

36

In the case of SARS-CoV-2, the nature of the immune response following natural infection 37 remains uncertain, although efforts to measure the kinetic adaptive immune response are on-38 going (12-16). One approach for bounding estimates for this immune response is to examine 39 related viruses that also belong to the β -CoV genus. This genus comprises other viruses that 40 cause severe infections in humans including the Middle East Respiratory Syndrome (MERS) 41 and SARS-CoV-1 coronaviruses (7) as well as the seasonal coronaviruses HCoV-HKU1 and 42 HCoV-OC43, which are the second leading causes of the common cold (7). While immunity to 43 SARS-CoV-1 is believed to last up to 2-3 years (17, 18), serum antibody levels against HCoV-44 OC43 have been found to wane on the time-scale of a few months (19) to one year (20) likely 45 due in part to a combination of antigenic evolution and low antigenic dose. HCoV-HKU1 and 46 HCoV-OC43 are thought to cause repeated infections throughout life (21), though a significant 47 biennial component in their dynamics implies at least some herd protection (7,8). Furthermore, 48 although it is currently unclear whether ADE influences the pathogenesis of SARS-CoV-2, it has 49 been hypothesized that severe Covid-19 cases may arise from the presence of non-neutralizing 50 antibodies from prior coronavirus infections (22) following earlier proposals for related coron-51 aviruses (23-25). For example, one study found that a subset of reinfections with three endemic 52 human coronaviruses (HCoV-NL63, HCoV-229E, and HCoV-OC43) showed enhanced viral 53

Figure 1: Schematic of the SIR(S) model with a flowchart depicting flows between immune classes. Here, S_P denotes fully susceptible individuals; I_P denotes individuals with primary infection that transmit at rate β ; R denotes fully immune individuals (due to recovery from either primary or secondary infection), S_S denotes individuals whose immunity has waned at rate δ and are now susceptible again to infection, with relative susceptibility ϵ ; I_S denotes individuals with secondary infection that transmit at a reduced rate $\alpha\beta$, and μ denotes the birth rate (see Methods). Illustrations and flowcharts of the limiting SIR and SIRS models are also shown (where individuals are either fully susceptible (S), infected (I), or fully immune (R)), along with a representative time series for the number of infections in each scenario. The population schematics were made through Biorender.com.

replication during the secondary infection (*26*). In addition to antibody-mediated immunity, T cell immunity increasingly appears to be an important component of the adaptive immune response to SARS-CoV-2; also there is evidence of T cell cross-reactivity between SARS-CoV-2 and these seasonal, endemic coronaviruses (*15*, *16*).

58

Various epidemiological models have been developed to capture this type of variation in im-59 mune responses on population-level infection dynamics. For instance, the well-known Susceptible-60 Infectious-Recovered (SIR) model is suitable for modeling the dynamics of perfectly-immunizing 61 infections such as measles (27), while the Susceptible-Infectious-Recovered-Susceptible (SIRS) 62 model captures the epidemiology of imperfectly immunizing infections such as influenza, in 63 which individuals eventually return to a fully or substantially susceptible class following a finite 64 period of immunity either due to waning memory or pathogen evolution (28). More complex 65 compartmental models have also been developed to study infections characterized by interme-66 diate immune responses lying between these two extremes such as rotavirus (29) and respiratory 67 syncytial virus (4). 68

69

Here we adopt a generalization of these more nuanced models, the SIR(S) model (28) out lined schematically in Figure 1 and Figure S1, to explore how the pandemic trajectory might

unfold for different assumptions regarding the nature of the adaptive immune response to SARS-72 CoV-2 infection. Since different adaptive immune responses may be associated with variations 73 in the proportion of severe secondary cases, we also consider different scenarios for this fraction 74 in order to estimate the future clinical burden of SARS-CoV-2 infections. The model assumes 75 different infection and immune phenotypes depending on exposure history (see Methods for the 76 full mathematical details). Specifically, it interpolates between the fully immunizing SIR model 77 when immunity is lifelong and the imperfectly immunizing SIRS model through the degree of 78 susceptibility to and transmissibility of secondary infections (quantified by the parameters ϵ and 79 α , respectively). As shown in the representative time series of Figure 1, the SIR model results in 80 recurrent epidemics fueled by births following the pandemic peak, while the SIRS model results 81 in shorter inter-epidemic periods due to the possibility of reinfection and the buffering of the 82 fully susceptible birth cohort by partially immune individuals (28). We begin by characterizing 83 the effect of temporal changes in the transmission rate brought about by climate and the adop-84 tion of NPIs on the predictions of the SIR(S) model under a range of immunity assumptions. 85 Next, we examine the effect of a transmission-reducing vaccine of varying efficacy relative to 86 natural immunity, thus altering the relative compositions of the various immune classes. Fi-87 nally, we estimate the post-pandemic immunity landscape and clinical case burden for different 88 possible 'futures' shaped by the various aspects of SARS-CoV-2 biology as well as the presence 89 or absence of these external drivers and interventions. 90

91

Results and Discussion

⁹³ Seasonal transmission rates and the adoption of NPIs

In practice, during the early stages of a pandemic, reductions in transmission are nearly entirely
 achieved through the adoption of NPIs such as mask-wearing or social distancing. To explore

the effect of the adoption of NPIs, we considered two different scenarios for timed reductions 96 in the force of infection to 60% of its original value (in agreement with intermediate levels of 97 social distancing in (7)). In Figures 2a - 2c, we plot the time series of primary and secondary 98 infections assuming NYC climate-driven seasonality in transmission as well as single periods of 99 NPI adoption lasting from weeks 16 to 67 (Figure 2a) or 16 to 55 (Figure 2b), and two shorter 100 periods during weeks 16 to 55 and weeks 82 to 93 separated by normal interactions (Figure 101 2c). The weekly reproduction numbers corresponding to these three scenarios are plotted in 102 Figures S2d-S2f. Although these reproduction numbers are based on those obtained for the re-103 lated β -CoV HCoV-HKU1 and are in general lower than those estimated during the early stages 104 of the Covid-19 pandemic (30), they may be more appropriate for considering the longer-term 105 transmission dynamics, and our results are qualitatively robust to increasing these values for R_0 106 (results not shown). 107

108

We find that decreases in the susceptibility to secondary infection ϵ can delay secondary 109 peaks (compare individual time courses for different values of ϵ in Figures 2a–2c). However, 110 delayed peaks may then be larger, due to susceptible accumulation and dynamical resonance. 111 These non-monotonicities in the timing and size of secondary peaks also occur with climate-112 driven seasonal transmission in the absence of NPIs (see Supplementary Materials, Section 113 S3.3). Importantly, the delay that social distancing may cause in the timing of the secondary 114 peak can also allow for the accumulation of fully susceptible individuals. This is illustrated in 115 the top panels of Figure 2d, where the full (βS_P , red curve) and partial ($\epsilon \beta S_S$, green curve) 116 effective population-level susceptibility corresponding to a reduction in susceptibility to sec-117 ondary infection by 50% ($\epsilon = 0.5$) (left) and with no reduction in susceptibility to secondary 118 infection ($\epsilon = 1$) (right) for the social distancing scenario outlined in Figure 2c are shown. The 119 corresponding fraction of primary (blue) and secondary (purple) cases are presented in the bot-120

Figure 2: (a) to (c): Effect of NPI adoption on the time series of primary (solid lines) and secondary (dashed lines) infections with a seasonal transmission rate derived from the climate of NYC with no lag between seasonality and epidemic onset. NPIs that reduces the transmission rate to 60% of the estimated climate value are assumed to be adopted during weeks 16-67 in (a), weeks 16-55 in (b), and weeks 16-55 as well as 82-93 in (c). Colours denote individual time courses for different values of ϵ . (d) Time series of the force of infection arising from susceptibility (top row) and the fraction of the population that is infected (bottom row) for both primary and secondary infections, for $\epsilon = 0.5$ (left column) and $\epsilon = 1$ (right column) for the NPI scenario outlined in (c). (e) Time series of estimated number of severe infections for the NPI scenario defined in (c) for four different estimates of the fraction of severe cases during primary infections ($x_{\text{SeV},p}$) and secondary infections ($x_{\text{SeV},p}$) with $\epsilon = 0.5$ (top row) and $\epsilon = 1$ (bottom row). These are $x_{\text{SeV},p} = 0.14$, $x_{\text{SeV},s} = 0$ (solid red line), $x_{\text{SeV},p} = 0.14$, $x_{\text{SeV},p} = 0.14$, $x_{\text{SeV},p} = 0.14$, $x_{\text{SeV},p} = 0.14$ (dashed-dotted blue line), and $x_{\text{SeV},p} = 0.14$, $x_{\text{SeV},p} = 0.14$.

tom panels. As can be seen, when the secondary peak does occur, the decrease in susceptibility to secondary infection ($\epsilon < 1$) considered in the left panels results in a greater number of primary infections during the second peak relative to the panels on the right where $\epsilon = 1$.

124

Finally, an essential part of the planning and management of future SARS-CoV-2 infections 125 is the ability to characterize the magnitude and timing of severe cases requiring hospitaliza-126 tion. In Figure 2e we consider four different plausible scenarios for the fraction of severe 127 secondary cases $x_{SeV,s}$ (see Methods) based on the scenario depicted in Figure 2c and assum-128 ing 14% of primary cases are severe (31): no severe cases associated with secondary infection 129 $(x_{\text{SeV},s} = 0, \text{ solid red line})$, a reduced number of severe cases with secondary infection rela-130 tive to primary infection ($x_{sev,s} = 0.07$, dashed green line), comparable proportions of severe 131 cases ($x_{\text{Sev},s} = 0.14$, dashed-dotted blue line), and a greater proportion of severe cases with 132 secondary infection ($x_{sev,s} = 0.21$, shortdashed-longdashed purple line), possibly owing to 133 phenomena such as ADE. When the assumed fraction of severe secondary infections is high, 134 the fraction of the population with severe infections during secondary peaks exceeds that ob-135

served during the primary peak (Figure 2e). As the proportion of secondary infections increases
during the later stages of the pandemic, these findings stress that clinical epidemiological studies of repeat infections will be critical for proper planning of healthcare systems.

139 Vaccination

The availability of an effective vaccine would be a key intervention against SARS-CoV-2, and 140 numerous candidates are in development (32, 33). Intuitively, if the effective vaccination rate 141 is sufficiently high, then vaccination herd immunity generated by a transmission-blocking vac-142 cine could control or eliminate the infection. However, this becomes harder to achieve when 143 vaccinal and natural immunity is imperfect and secondary infections occur, or when logistical 144 or other constraints limit vaccine deployment. Although it remains uncertain whether and when 145 a vaccine will be available, we make the relatively optimistic assumption that a transmission-146 reducing vaccine begins to be introduced at $t_{\text{Vax}} = 1.5$ years. We also consider seasonal 147 transmission rates as in Figure S3 and the adoption of NPIs according to the scenario described 148 in Figure 2b. We assume that a constant proportion ν ranging from $0\% \le \nu \le 1\%$ of the fully 149 and partially susceptible populations (S_P and S_S) is effectively vaccinated every week and ac-150 quire transmission-blocking immunity for, on average, a period $1/\delta_{vax}$. For comparison, it was 151 estimated that in response to the 2009 H1N1 pandemic, one or more doses of the monovalent 152 vaccine were administered to 80.8 million vaccinees during October 2009 to May 2010 in the 153 United States (34), which implies a rate of vaccination coverage of about 27% after a period 154 of 8 months for persons aged at least 6 months in the USA, although rates between different 155 nations varied (35). This crudely corresponds to a weekly vaccination rate of 1% (36). Finally, 156 we assume that the immunity conferred from effective vaccination wanes at rate δ_{Vax} which in 157 general may differ from the waning rate of immunity from natural infection, δ . The modified 158 set of ordinary differential equations in this scenario corresponding to the flowchart in Figure 159

¹⁶⁰ S11a is presented in the Methods.

161

In Figure 3a we consider the long-term equilibrium infection burden (see Methods) fol-162 lowing vaccination at a weekly rate ν for a variety of immunity assumptions. As expected, a 163 reduction in the susceptibility to secondary infections (ϵ) results in a smaller number of infec-164 tions at steady state in the absence of vaccination. Further, both ϵ and the duration of vaccine 165 immunity $(1/\delta_{\text{Vax}})$ affect the vaccination rate required to achieve a disease-free state at equi-166 librium. In the limit of fully immunizing primary infections and vaccines ($\epsilon = 0$), relatively 167 low vaccination rates are required to achieve zero infections at steady state. However, as im-168 munity becomes more imperfect (larger ϵ), increasingly high vaccination rates are required to 169 eliminate infections particularly when the duration of vaccine immunity is short. This is further 170 emphasized in Figure 3b, where the minimum vaccination rate ν required to achieve a disease-171 free state at equilibrium (see Methods) is plotted as a function of ϵ for different values of the 172 duration of vaccine immunity. Altogether, this illustrates that reductions in infection achievable 173 through vaccination are inherently related to the efficacy of the vaccine and the nature of the 174 adaptive immune response (37). 175

176

We next explore the short-term dynamical effect of vaccination in Figures 3c-3f. In Figure 177 S11b, the ratio of the total number of primary infections during years 1.5-5 inclusive (i.e. after 178 the vaccine is introduced) relative to the zero vaccination case for different values of the vac-179 cination rate ν and the duration of vaccine immunity $1/\delta_{\text{Vax}}$ is shown. Figure S11c shows the 180 equivalent for secondary infections. The burden of primary infections decreases with increas-181 ing vaccination rate for a given value of vaccine immunity $1/\delta_{\text{Vax}}$. However, for the shortest 182 durations of vaccine immunity $1/\delta_{\text{Vax}}$, the degree of achievable reductions in the number of 183 secondary cases begins to saturate even for large vaccination rates. This saturation is due to the 184

Figure 3: (a) Total infected fraction of the population at equilibrium as a function of the vaccination rate ν for different values of the duration of vaccine immunity ($1/\delta_{\text{Vax}} = 0.25$ years: green line, $1/\delta_{\text{Vax}} = 0.5$ years: red line, and $1/\delta_{\text{Vax}} = 1$ year: blue line) and the susceptibility to secondary infection ($\epsilon = 0.5$: solid line, $\epsilon = 0.7$: dashed line, and $\epsilon = 1$: dotted line). (b) Vaccination rate ν required to achieve a disease-free state at equilibrium as a function of ϵ for different values of the duration of vaccine immunity ($1/\delta_{\text{Vax}} = 0.25$ years: solid line, $1/\delta_{\text{Vax}} = 0.5$ years: dashed line, and $1/\delta_{\text{Vax}} = 1$ year: dotted line). In (a) and (b) the relative transmissibility of secondary infections and duration of natural immunity are taken to be $\alpha = 1$ and $1/\delta = 1$ year, respectively, and the transmission rate is derived from the mean value of seasonal NYC-based weekly reproduction numbers ($\overline{R}_0 = 1.75$, see Methods and Figure S2c). (c)-(f): Time series of the various immune classes plotted for different values of the vaccination rate ν . The top row ((c) and (e)) contains the time series of primary (solid lines) and secondary (dashed lines) infections, while the bottom row ((d) and (f)) contains the time series of the fully susceptible (solid lines), immune (dashed lines), and partially immune (dotted lines) subpopulations. The duration of vaccine immunity is taken to be $1/\delta_{\text{Vax}} = 0.5$ years (shorter than natural immunity) in (c) and (d), and $1/\delta_{\text{Vax}} = 1$ year (equal to natural immunity) in (e) and (f). The susceptibility to secondary infection, relative transmissibility of secondary infections, and duration of natural immunity are taken to be $\epsilon = 0.7$, $\alpha = 1$, and $1/\delta = 1$ year, respectively. Vaccination is introduced 1.5 years after the onset of the epidemic following a 40 week period of social distancing during which the force of infection was reduced to 60% of its original value during weeks 16 to 55 (i.e. the scenario described in Figure 2b of the main text), and a seasonal transmission rate derived from the climate of NYC with no lag is assumed.

Figure 4: Time series of fraction of the population with severe cases I_{SeV} (top) and area plots of the fraction of the population comprising each immune class (bottom) over a five year time period under four different future scenarios. In all plots, the relative transmissibility of secondary infections is taken to be $\alpha = 1$, a seasonal transmission rate derived from the climate of NYC with no lag is assumed, and a period of social distancing during which the force of infection is reduced to 60% of its original value during weeks 16 to 55 (i.e. the scenario described in Figure 2b) is enforced. In (a) and (b), no vaccination occurs. (a) Corresponds to a more pessimistic natural immunity scenario with $\epsilon = 0.7$, $1/\delta = 0.5$ years, and 21% of secondary cases being severe. (b) Corresponds to a more optimistic natural immunity scenario with $\epsilon = 0.5$, $1/\delta = 2$ years, and 7% of secondary cases being severe. In (c) and (d), vaccination is introduced at a weekly rate of $\nu = 1\%$ at $t_{\text{Vax}} = 1.5$ years after the onset of the epidemic. (c) Corresponds to all the parameters in (b) along with vaccine immunity lasting $1/\delta_{\text{Vax}} = 0.25$ years, while (d) corresponds to all the same parameters as in (b) along with vaccine immunity lasting $1/\delta_{\text{Vax}} = 1$ year.

rapid return of vaccinated individuals to the partially susceptible class if vaccine immunity is 185 short-lived. Further, when the duration of vaccine immunity is very short, the total number of 186 secondary cases can be higher when vaccination takes place for the particular model and param-187 eters considered. To further emphasize the dependence of the model results on the vaccination 188 rate and duration of vaccine immunity, we present time courses of infections and immunity for 189 different durations of vaccine immunity and vaccination rates in Figures 3c - 3f as well as Fig-190 ures S11d and S11e. In line with intuition, the model illustrates that both high vaccination rates 191 and relatively long durations of vaccine-induced immunity are required to achieve the largest 192 reductions in secondary infection burdens. 193

194

¹⁹⁵ Clinical case burden and immunity landscape for different possible futures

Figure 4 is a synoptic view of the impact of vaccination and natural immunity in four different futures' on the immune landscape and incidence of severe disease. In all four scenarios, we assume seasonal transmission (c.f. Figure S3) and social distancing according to the scenario depicted in Figure 2b. Figures 4a and 4b correspond to futures without vaccination, with Fig-

ure 4a illustrating a more pessimistic scenario of greater susceptibility to secondary infections 200 $(\epsilon = 0.7)$, a relatively short period of natural immunity $(1/\delta = 0.5$ years), and a greater pro-201 portion of severe cases with secondary infection possibly owing to phenomena such as ADE. In 202 contrast, the more optimistic future of Figure 4b assumes reduced susceptibility to secondary 203 infections ($\epsilon = 0.5$), a longer duration of natural immunity ($1/\delta = 2$ years), and a smaller 204 proportion of severe cases with secondary infection. In both cases, the initial pandemic wave 205 is the same, but in the more optimistic scenario (Figure 4b), natural immunity is longer lasting 206 and consequently subsequent infection peaks are delayed. Furthermore, the reduction in sus-207 ceptibility to secondary infection (smaller ϵ) in Figure 4b suppresses the later peaks dominated 208 by secondary infections (Figure 4a) and substantially less depletion of fully susceptible indi-209 viduals occurs. In Figures 4c and 4d, these pessimistic and optimistic scenarios are translated 210 into futures with vaccination, which is assumed to be introduced at a weekly rate of $\nu = 1\%$ at 211 $t_{\text{Vax}} = 1.5$ years. The future described in Figure 4c assumes all the same outcomes as in Fig-212 ure 4a and incorporates vaccination with short-lived vaccine immunity $(1/\delta_{\text{Vax}} = 0.25 \text{ years})$. 213 The future presented in Figure 4d assumes all the same outcomes as in Figure 4b in addition to 214 vaccine immunity lasting $1/\delta_{\text{Vax}} = 1$ year. 215

216

Figures 4c and 4d emphasize the important role that even an imperfect vaccine could have 217 in SARS-CoV-2 dynamics and control (9, 11). With vaccination, subsequent peaks in clinically 218 severe cases are substantially reduced, although in the pessimistic future later infection peaks 219 dominated by secondary infections can still occur (Figure 4c). Furthermore, if a transmission-220 blocking vaccine confers a relatively long period of protection, and if we make optimistic as-221 sumptions regarding the nature of the adaptive immune response (Figure 4d), a sufficient pro-222 portion of fully susceptible individuals can be immunized, thus suppressing future outbreaks. 223 These trends are qualitatively conserved for different vaccine deployment strategies, such as a 224

pulse of immunization at $t_{\text{Vax}} = 1.5$ years in which a fixed percentage of the fully and par-225 tially susceptible populations (S_P and S_S) are vaccinated (see Figure S12). However, without 226 sustained immunization strategies, the waning of vaccine immunity results in less susceptible 227 depletion over time, and larger future outbreaks relative to the scenarios presented in Figures 228 4c and 4d. Overall, Figure 4 suggests that relying on the status of infection of an individual 229 as the main observable during an ongoing epidemic is insufficient to characterize the complex 230 immune landscape that is generated. Given the increasingly recognized importance of both T 231 cell- (15, 16) and antibody-mediated (12-14) adaptive immune responses in the recovery from 232 SARS-CoV-2 infection, it is very likely that more sophisticated methods including regular test-233 ing of serology and T cell immunity will be required (38). 234

235

236 Conclusion

We have examined how plausible variations in the natural immune response following SARS-CoV-2 infection as well as various external drivers and interventions may shape the longer-term clinical burden and immunity landscape to this disease. Here we summarize the key findings and complexities illustrated by this simple model along with caveats for their interpretation; a full summary of all caveats and future directions is given in Section S2.

242

In locations where we expect substantial climatically-driven seasonal variation in transmission, such as New York City, the model predicts that a reduction in susceptibility to secondary infection or a longer duration of immunity may lead to a larger secondary infection peak, and this peak may occur earlier when the duration of natural immunity is longer. In geographical areas with smaller annual fluctuations in climate, we find that this non-monotonic behaviour is increasingly suppressed, although these results are sensitive to the assumed form of climatic

influences on SARS-CoV-2 transmission, which we have taken here to be very similar to those 249 of the related β -CoV HCoV-HKU1. Indeed, even with the incorporation of NPIs (which in 250 general may be adopted differently than the scenarios considered here), the clinical burden of 251 subsequent infection peaks is sensitive to the relative fraction of primary and secondary cases as 252 well as the fraction of severe cases for each category, which intimately depend on the nature of 253 the adaptive immune response. In turn, the severity of an infection could affect the nature of the 254 subsequent adaptive immune response through antigen priming or T cell exhaustion. Finally, 255 the disease dynamics predicted by the model can be substantially altered using a highly simpli-256 fied scenario for the introduction of a vaccine, although the achievable reductions in infections 257 are strongly dependent on the efficacy of the vaccine and the nature of the adaptive immune 258 response. Nevertheless, even with imperfect vaccine immunity, reductions in the number of 259 primary cases through vaccination may have important clinical implications. 260

261

Altogether, this work emphasizes the complex dependence of the immune landscape generated by SARS-CoV-2 infection on the presently largely unknown nature of the adaptive immune response to this virus and the efficacy of potential future vaccines. Depending on how these unfold, the model predictions for future clinical burdens range from sustained epidemics to near case elimination. Consequently, accurately characterizing the nature of immunity to SARS-CoV-2 will be critical for the management and control of future infections.

Acknowledgements

CMSR acknowledges support from the Natural Sciences and Engineering Research Council of Canada through a Postgraduate-Doctoral Scholarship. CEW is an Open Philanthropy Project fellow of the Life Sciences Research Foundation. REB is supported by the Cooperative Institute for Modelling the Earth System (CIMES). SAL and CMSR acknowledge support from the

James S. McDonnell Foundation 21st Century Science Initiative Collaborative Award in Understanding Dynamic and Multi-scale Systems. SAL acknowledges support from the C3.ai Digital Transformation Institute, the National Science Foundation under grant CNS-2027908, and the National Science Foundation Expeditions Grant CCF1917819. BTG acknowledges support from the US CDC.


278 **References**

- 1. B. M. Laksono, R. D. de Vries, S. McQuaid, W. P. Duprex, R. L. de Swart, *Viruses* 8, 1 (2016).
- ²⁸¹ 2. P. D. Ellner, *Infection*, **3**, 5, 1998.
- 3. J. D. Dushoff, J. B. Plotkin, S. A. Levin, D. J. D. Earn, R. D., *Proceedings of the National Academy of Sciences* 101, 48 (2004).
- ²⁸⁴ 4. V. E. Pitzer, *et al.*, *PLoS Pathogens* **11**, 1 (2015).
- 5. N. Ferguson, R. Anderson, S. Gupta, *Proceedings of the National Academy of Sciences* 96, 790 (1999).
- ²⁸⁷ 6. B. S. Graham, *Science* **368**, 6494 (2020).
- ²⁸⁸ 7. M. Kissler, C. Tedijanto, E. Goldstein, Y. H. Grad, M. Lipsitch, *Science* **368**, 6493 (2020).
- 8. R. E. Baker, W. Yang, G. A. Vecchi, C. J. E. Metcalf, B. T. Grenfell, *Science* 10.1126/science.abc2535 (2020).
- ²⁹¹ 9. S. Gandon, M. J. Mackinnon, S. Nee, A. F. Read, *Nature* **414**, 751 (2001).
- ²⁹² 10. G. Anichini, et al., Vaccines 8, 1 (2020).


- ²⁹³ 11. N. Arinaminpathy, et al., American Journal of Epidemiology 186, 92 (2017).
- ²⁹⁴ 12. J. Huang, et al., medRxiv 2020.04.22.20071258 (2020).
- ²⁹⁵ 13. N. M. A. Okba, et al., medRxiv 2020.03.18.20038059 (2020).
- ²⁹⁶ 14. W. Tan, et al., medRxiv 2020.03.24.20042382 (2020).
- ²⁹⁷ 15. A. Grifoni, et al., Cell 181, (2020).
- ²⁹⁸ 16. J. Braun, *et al.*, *medRxiv* 2020.04.17.20061440 (2020).
- ²⁹⁹ 17. W. Liu, et al., The Journal of Infectious Diseases **193**, 792 (2006).
- 18. W.-C. Cao, W. Liu, P.-H. Zhang, F. Zhang, J. H. Richardus, New England Journal of
 Medicine 357, 1162 (2007).
- ³⁰² 19. M. R. Macnaughton, *Infection and Immunity* **38**, 419 (1982).
- 20. K. A. Callow, H. F. Parry, M. Sergeant, D. A. J. Tyrrell, *Epidemiology and Infection* 105,
 435 (1990).
- 21. E. R. Gaunt, A. Hardie, E. C. Claas, P. Simmonds, K. E. Templeton, *Journal of Clinical Microbiology* 48, 2940 (2010).
- ³⁰⁷ 22. J. A. Tetro, *Microbes and Infection* **22**, 72 (2020).
- ³⁰⁸ 23. M. Jaume, *et al.*, *Hong Kong Medical Journal* **18**, 31 (2012).
- ³⁰⁹ 24. M. S. Yip, et al., Virology Journal **11**, 1 (2014).
- ³¹⁰ 25. M. S. Yip, et al., Hong Kong Medical Journal 22, 25 (2016).
- 26. P. K. Kiyuka, et al., Journal of Infectious Diseases 217, 1728 (2018).

- ³¹² 27. A. D. Becker, B. Grenfell, *PLoS ONE* **12**, e0185528 (2017).
- 28. S. E. Morris, et al., Journal of the Royal Society Interface 12 (2015).
- ³¹⁴ 29. V. E. Pitzer, *et al.*, *Science* **325**, 290 (2009).
- 315 30. S. W. Park, *et al.*, *medRxiv* 2020.01.30.20019877 (2020).
- 316 31. Z. Wu, J. M. McGoogan, JAMA 323, 13 (2020).
- 317 32. M. J. Mulligan, et al., medRxiv 2020.06.30.20142570 (2020)
- 318 33. N. van Doremalen, *et al.*, *bioRxiv* 2020.05.13.093195 (2020)
- ³¹⁹ 34. Final estimates for 2009–10 Seasonal Influenza and Influenza A (H1N1) 2009 Monovalent
 ³²⁰ Vaccination Coverage United States, August 2009 through May, 2010 (2011).
- 321 35. Statistics Canada (2015)
- https://www150.statcan.gc.ca/n1/pub/82-003-x/2010004/article/11348/findings-resultatseng.htm.
- 36. Assuming a simplified scenario in which a constant proportion of the total population is vaccinated weekly, the proportion of the population that is not vaccinated U can be modeled to decrease exponentially in time as $U(t) = \exp(-\nu t)$. Consequently, in order to achieve 27% vaccination coverage after an 8 month (or 34.7 week) period (i.e. U(34.7) = 0.73), a weekly vaccination rate of 0.91% of the remaining unvaccinated population would be required.
- 37. M. E. Halloran, *et al.*, *Design and analysis of vaccine studies* (Springer, New York, 2010),
 Vol 18.
- 332 38. M. J. Mina, et al., eLife 9, 1 (2020).


1 med Rvv preprint doi: https://doi.org/10.1101/2020.07.15.20154401; this version posted July 16, 2020. The copyright holder for this preprint (waicrevent doi: https://doi.org/10.1101/2020.07.15.20154401; this version posted July 16, 2020. The copyright holder for this preprint (waicrevent doi: https://doi.org/10.1101/2020.07.15.20154401; this version posted July 16, 2020. The copyright holder for this preprint (waicrevent doi: https://doi.org/10.1101/2020.07.15.20154401; this version posted July 16, 2020. The copyright holder for this preprint (waicrevent doi: https://doi.org/10.1101/2020.07.15.20154401; this version posted July 16, 2020. The copyright holder for this preprint It is made available under a CC-BY-NC-ND 4.0 International license .




2 Figure 2



3 Figure 3



4 Figure 4



4